IMAB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

I-Mab

NASDAQ | IMAB

6.37

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 16, 2025)

$698.51M

Market Cap

-

P/E Ratio

-0.51

EPS

$6.72

52 Week High

$0.59

52 Week Low

HEALTHCARE

Sector

IMAB Chart

Recent Chart
Price Action

IMAB Technicals

Tags:

IMAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

Revenue & Profitability

Earnings Performance

IMAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $177M
Cash And Cash Equivalents At Carrying Value $68M
Cash And Short Term Investments $68M
Inventory -
Current Net Receivables $1.2M
Total Non Current Assets $36M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $31M
Short Term Investments $105M
Other Current Assets $2.1M
Other Non Current Assets -
Total Liabilities $12M
Total Current Liabilities $8.5M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $816K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $3.9M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.9M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $201M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $19K
Common Stock Shares Outstanding $81M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$53M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $978K
Capital Expenditures $48K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$136M
Cashflow From Financing -$335K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$335K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$50M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$375M
Selling General And Administrative $216M
Research And Development $159M
Operating Expenses $375M
Investment Income Net -
Net Interest Income $7.5M
Interest Income $7.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.9M
Income Before Tax -$363M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$50M
Comprehensive Income Net Of Tax -
Ebit -$375M
Ebitda -$373M
Net Income -$162M

IMAB News

IMAB Profile

I-Mab Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the potential to drive meaningful advancements in healthcare and improve patient outcomes.

GNPX
+232.67%
$0.84
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
BURU
-17.95%
$0.33
VIVK
+52.49%
$0.45
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
RXRX
+15.28%
$6.79
BITF
+9.84%
$6.47
DFLI
+28.75%
$1.97
CAN
+8.88%
$1.96
OMER
+154.14%
$10.42
TLRY
+5.00%
$1.68
BYND
-14.17%
$0.67
DNN
-0.62%
$3.17
LAES
-2.09%
$7.49
AMD
+9.40%
$238.60
RR
-8.46%
$6.16
INTC
+4.26%
$37.15
ACHR
+0.07%
$13.03
SCNX
+8.89%
$0.77
ADAP
+15.06%
$0.18
MIRA
+67.04%
$2.20
TSLA
+1.37%
$435.15
IONZ
+12.06%
$2.88
BAC
+4.37%
$52.28
AXDX
-61.36%
$0.03
NOK
+3.29%
$5.65
CIFR
+0.67%
$21.03
FHN
-9.42%
$20.85
UUUU
-4.72%
$24.99
MARA
+2.69%
$22.84
PLUG
+2.88%
$3.96
NIO
-0.73%
$6.76
BTG
+6.17%
$5.67
HIMS
+16.17%
$62.76
QSI
+22.32%
$2.63
APLD
+7.76%
$37.76
NAK
-4.34%
$2.64
HPE
+0.16%
$25.04
JOBY
-2.81%
$17.60
ONDS
-8.64%
$9.51
DVLT
-4.10%
$2.10
IREN
-2.27%
$67.98
PFE
-0.53%
$24.39
WHWK
+56.42%
$3.28
SLNH
+53.76%
$4.29
GDXD
-12.00%
$0.66
WULF
+0.06%
$15.47
CLSK
+5.55%
$23.20
TMQ
-20.18%
$8.46
SEED
+36.58%
$1.96
RGTZ
-1.13%
$8.69
NVDA
+1.59%
$182.70
SNAP
-0.12%
$7.91
RMBL
+60.50%
$3.21
YDKG
-15.79%
$0.16
ADD
-25.47%
$0.05
GRAB
+0.16%
$5.92
PLTR
-0.06%
$179.62
CGC
+7.35%
$1.46
RF
-1.66%
$24.74
NUAI
+9.12%
$3.35
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
T
-0.22%
$26.07
NAKA
+1.29%
$0.79
KDLY
+1.29%
$0.79
HI
+18.19%
$31.31
IONQ
-6.62%
$72.41
WOK
-22.55%
$0.05
PBR
-1.27%
$11.64
ABEV
+0.46%
$2.17
RGTI
-6.85%
$52.47
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
RZLV
+0.18%
$5.46
EPWK
-7.47%
$0.07
NVTS
+1.51%
$15.39
VSEE
+61.72%
$0.97
ETWO
0.00%
$3.30
ASPI
-10.17%
$12.62
SERV
+6.44%
$17.51
ITUB
+0.14%
$6.87
KEY
-1.55%
$17.73
AVGO
+2.09%
$351.33
INFY
-0.24%
$16.44
AFMD
-34.94%
$0.18
SBFM
+15.03%
$2.22
JBLU
+0.81%
$4.95
WFC
+2.24%
$86.46
CRML
-1.54%
$22.37
OPI
-16.97%
$0.20
IXHL
-0.10%
$0.38
ABAT
-28.38%
$6.40
BTE
+1.73%
$2.35
MVST
+19.04%
$6.25
KLG
-9.05%
$13.35
GRYP
-10.38%
$1.38
GNPX
+232.67%
$0.84
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
BURU
-17.95%
$0.33
VIVK
+52.49%
$0.45
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
RXRX
+15.28%
$6.79
BITF
+9.84%
$6.47
DFLI
+28.75%
$1.97
CAN
+8.88%
$1.96
OMER
+154.14%
$10.42
TLRY
+5.00%
$1.68
BYND
-14.17%
$0.67
DNN
-0.62%
$3.17
LAES
-2.09%
$7.49
AMD
+9.40%
$238.60
RR
-8.46%
$6.16
INTC
+4.26%
$37.15
ACHR
+0.07%
$13.03
SCNX
+8.89%
$0.77
ADAP
+15.06%
$0.18
MIRA
+67.04%
$2.20
TSLA
+1.37%
$435.15
IONZ
+12.06%
$2.88
BAC
+4.37%
$52.28
AXDX
-61.36%
$0.03
NOK
+3.29%
$5.65
CIFR
+0.67%
$21.03
FHN
-9.42%
$20.85
UUUU
-4.72%
$24.99
MARA
+2.69%
$22.84
PLUG
+2.88%
$3.96
NIO
-0.73%
$6.76
BTG
+6.17%
$5.67
HIMS
+16.17%
$62.76
QSI
+22.32%
$2.63
APLD
+7.76%
$37.76
NAK
-4.34%
$2.64
HPE
+0.16%
$25.04
JOBY
-2.81%
$17.60
ONDS
-8.64%
$9.51
DVLT
-4.10%
$2.10
IREN
-2.27%
$67.98
PFE
-0.53%
$24.39
WHWK
+56.42%
$3.28
SLNH
+53.76%
$4.29
GDXD
-12.00%
$0.66
WULF
+0.06%
$15.47
CLSK
+5.55%
$23.20
TMQ
-20.18%
$8.46
SEED
+36.58%
$1.96
RGTZ
-1.13%
$8.69
NVDA
+1.59%
$182.70
SNAP
-0.12%
$7.91
RMBL
+60.50%
$3.21
YDKG
-15.79%
$0.16
ADD
-25.47%
$0.05
GRAB
+0.16%
$5.92
PLTR
-0.06%
$179.62
CGC
+7.35%
$1.46
RF
-1.66%
$24.74
NUAI
+9.12%
$3.35
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
T
-0.22%
$26.07
NAKA
+1.29%
$0.79
KDLY
+1.29%
$0.79
HI
+18.19%
$31.31
IONQ
-6.62%
$72.41
WOK
-22.55%
$0.05
PBR
-1.27%
$11.64
ABEV
+0.46%
$2.17
RGTI
-6.85%
$52.47
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
RZLV
+0.18%
$5.46
EPWK
-7.47%
$0.07
NVTS
+1.51%
$15.39
VSEE
+61.72%
$0.97
ETWO
0.00%
$3.30
ASPI
-10.17%
$12.62
SERV
+6.44%
$17.51
ITUB
+0.14%
$6.87
KEY
-1.55%
$17.73
AVGO
+2.09%
$351.33
INFY
-0.24%
$16.44
AFMD
-34.94%
$0.18
SBFM
+15.03%
$2.22
JBLU
+0.81%
$4.95
WFC
+2.24%
$86.46
CRML
-1.54%
$22.37
OPI
-16.97%
$0.20
IXHL
-0.10%
$0.38
ABAT
-28.38%
$6.40
BTE
+1.73%
$2.35
MVST
+19.04%
$6.25
KLG
-9.05%
$13.35
GRYP
-10.38%
$1.38
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.